Jay Olson Oppenheimer & Co. Inc., Research Division. Hello, everyone, and welcome to Oppenheimer's 36th Annual Life Science Conference. I'm Jay Olson, one of the biotech analysts ...
Approval expands indication of JUXTAPID® to include children 2 years of age and older with HoFH. This announcement was made ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
Produce prescriptions and hospital food programs are expanding fast. But the real test isn’t medical—it’s financial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results